Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, 39002.
Servicio Cántabro de Salud.
Rev Esp Enferm Dig. 2020 Jul;112(7):565-570. doi: 10.17235/reed.2020.7108/2020.
The hepatitis C virus (HCV) is one of the leading causes of liver-related morbidity and mortality worldwide, affecting more than 70 million people. Approximately, between 55 % and 85 % of infected people will develop chronic HCV infection and between 15 % and 30 % of this group will develop liver cirrhosis and associated complications in the following 20-30 years. In our country, the seroprevalence of anti-HCV ranges from 0.8 to 1.2 % of adult population, while 0.2 % to 0.4 % show active HCV infection. In recent years, with the appearance of direct-acting antiviral agents (DAAs), which achieve cure rates of over 95 %, the elimination of HCV is a real possibility. In fact, in 2016 the World Health Organization (WHO) stablished a global strategy with the goal of achieving its elimination by 2030.
丙型肝炎病毒 (HCV) 是全球导致肝脏相关发病率和死亡率的主要原因之一，影响了超过 7000 万人。大约有 55%至 85%的感染者会发展为慢性 HCV 感染，而在这一人群中，15%至 30%的人会在接下来的 20 至 30 年内发展为肝硬化和相关并发症。在我国，成人人群的抗-HCV 血清流行率在 0.8%至 1.2%之间，而有 0.2%至 0.4%显示为活动性 HCV 感染。近年来，随着直接作用抗病毒药物 (DAAs) 的出现，其治愈率超过 95%，消除 HCV 成为了一种现实可能。事实上，2016 年世界卫生组织 (WHO) 制定了一项全球战略，目标是在 2030 年前实现消除 HCV。
